Central Mechanisms Regulating Macronutrient Intake
Central Mechanisms Regulating Macronutrient Intake
批准号:
10266052
负责人:
Matthew Joseph Potthoff
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-07-01 至 2023-06-30
关键词:
AddressAdultAffectAnimal ModelBehaviorBody WeightBody Weight decreasedBrainCarbohydratesCaringCenters for Disease Control and Prevention (U.S.)ComplexConsumptionDataDesire for foodDevelopmentDiabetes MellitusDopamineEndocrineEnergy IntakeEpidemicFatty acid glycerol estersFeedbackFeeding behaviorsFoodFood EnergyGenesGlutamatesGoalsGrantHealth Care CostsHealthcareHepaticHomeostasisHormonalHormonesHumanHypothalamic structureIntakeLipidsLiverMacronutrients NutritionMediatingMedicalMetabolic DiseasesMetabolic dysfunctionMetabolic syndromeModelingMotivationNeuraxisNeuronsNucleus AccumbensNutrientObesityOrganismOverweightOxytocinPathway interactionsPeripheralPharmacologyPhysiologicalPopulationProductionProteinsPublic HealthPublishingQuality of lifeRegulationResearchRewardsRodentRoleSatiationSignal TransductionSingle Nucleotide PolymorphismSourceSynapsesSynaptic plasticityTaste PerceptionTaste preferencesTimeVentral Tegmental AreaVeteransWaist-Hip RatioWeight Gainanalogblood glucose regulationburden of illnesscombatcompliance behaviorcosteconomic costfibroblast growth factor 21improvedin vivoinnovationinsightliver functionmesolimbic systemmetabolic profilemolecular targeted therapiesneural circuitnew therapeutic targetnovelnovel therapeuticsobesity treatmentparaventricular nucleuspreferencereceptor expressionsocialsugarsweet taste perceptiontool
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Obesity and diabetes are major public health issues that affect quality of life and also have high social and
economic costs. According to the CDC, approximately 10% of U.S. adults have diabetes now and 33% are
expected to have diabetes by 2050. At the same time, obesity has reached epidemic proportions, with over
60% of the U.S. population being overweight or obese. Therefore, there is a serious demand for the
development of new therapeutics to combat obesity and diabetes. Fibroblast growth factor 21 (FGF21) is an
endocrine hormone that ameliorates metabolic dysfunction in a number of obese animal models and humans.
Extended administration of FGF21 causes weight loss in rodents, and administration of FGF21 analogs to
obese humans increases weight loss and improves metabolic profiles. Recently, we discovered that FGF21
functions physiologically and pharmacologically to suppress carbohydrate intake and sweet taste preference.
Importantly, we and others have found that many of the beneficial effects of FGF21 are mediated through its
actions on the central nervous system. However, the mechanism of FGF21 action in the brain and the neuronal
target(s) for these effects has not been determined. The overall goal of this proposal is to identify the neural
circuit(s) regulating FGF21-mediated suppression of carbohydrate intake. The aims of this grant are to 1)
determine the direct neuronal target responsible for FGF21-mediated suppression of carbohydrate intake in
vivo, 2) determine the role of oxytocin signaling in FGF21’s suppressive effect on simple sugar intake, and 3)
determine the effect of FGF21 on the modulation of the mesolimbic dopamine system and feeding behavior. To
accomplish these aims, we have generated novel animal models and tools to examine these experimental
aims. These studies will provide new fundamental insights into the regulation of whole-body glucose
homeostasis and food-related reward by peripheral endocrine signals acting on the central nervous system. In
addition, these studies may identify novel therapeutic targets for the treatment of diabetes and obesity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Therapeutic Potential of FGF21 for Alzheimer’s Disease
-
批准号:10740063
-
项目类别:
-
资助金额:$59.07万
-
财政年份:2023
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Endocrine Regulation of Alcohol Intake
-
批准号:10289389
-
项目类别:
-
资助金额:$35.86万
-
财政年份:2020
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Endocrine Regulation of Alcohol Intake
-
批准号:9887298
-
项目类别:
-
资助金额:$45.08万
-
财政年份:2020
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Endocrine Regulation of Alcohol Intake
-
批准号:10083683
-
项目类别:
-
资助金额:$43.72万
-
财政年份:2020
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Endocrine Regulation of Alcohol Intake
-
批准号:10321634
-
项目类别:
-
资助金额:$43.72万
-
财政年份:2020
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Endocrine Regulation of Alcohol Intake
-
批准号:10544296
-
项目类别:
-
资助金额:$43.72万
-
财政年份:2020
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Central Mechanisms Regulating Macronutrient Intake
-
批准号:9974289
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2019
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Regulation of Energy Homeostasis by FGF21
-
批准号:10118923
-
项目类别:
-
资助金额:$52.41万
-
财政年份:2015
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Regulation of Energy Homeostasis by FGF21
-
批准号:10266143
-
项目类别:
-
资助金额:$52.41万
-
财政年份:2015
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Regulation of Energy Homeostasis by FGF21
-
批准号:10450711
-
项目类别:
-
资助金额:$52.41万
-
财政年份:2015
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Regulation of Energy Homeostasis by FGF21
-
批准号:10669576
-
项目类别:
-
资助金额:$52.41万
-
财政年份:2015
-
负责人:Matthew Joseph Potthoff
-
依托单位:
Regulation of Carbohydrate Metabolism by FGF21 Action on Brown Adipose Tissue
-
批准号:8942655
-
项目类别:
-
资助金额:$33.98万
-
财政年份:2015
-
负责人:Matthew Joseph Potthoff
-
依托单位:
海外基金